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Contxa Castell9, Elias Delgado  10,17,18, Edelmiro Menendez10,17,18, Josep Franch-Nadal2,11, 
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Previous studies have suggested that iron deficiency (ID) may impair thyroid hormone metabolism, 
however replication in wide samples of the general adult population has not been performed. We 
studied 3846 individuals free of thyroid disease, participants in a national, cross sectional, population 
based study representative of the Spanish adult population. Thyroid stimulating hormone (TSH), free 
thyroxin (FT4) and free triiodothyronine (FT3) were analyzed by electrochemiluminescence (E170, 
Roche Diagnostics). Serum ferritin was analyzed by immunochemiluminescence (Architect I2000, 
Abbott Laboratories). As ferritin levels decreased (>100, 30–100, 15–30, <15 µg/L) the adjusted 
mean concentrations of FT4 (p < 0.001) and FT3 (p < 0.001) descended, whereas TSH levels remained 
unchanged (p = 0.451). In multivariate logistic regression models adjusted for age, sex, UI, BMI and 
smoking status, subjects with ferritin levels <30 µg/L were more likely to present hypothyroxinemia 
(FT4 < 12.0 pmol/L p5): OR 1.5 [1.1–2.2] p = 0.024, and hypotriiodothyroninemia (FT3 < 3.9 pmol/L p5): 
OR 1.8 [1.3–2.6] p = 0.001 than the reference category with ferritin ≥30 µg/L. There was no significant 
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heterogeneity of the results between men, pre-menopausal and post-menopausal women or according 
to the iodine nutrition status. Our results confirm an association between ID and hypothyroxinemia and 
hypotriiodothyroninemia in the general adult population without changes in TSH.
Iron deficiency (ID) is the most prevalent nutritional deficiency worldwide1. It is a major public health problem 
with important adverse health consequences: It delays psychomotor development and affects cognitive perfor-
mance in children2. It causes damage to immune mechanisms, thereby increasing vulnerability to infectious dis-
eases3. ID seriously impairs the ability and physical performance of work in men and women4. During pregnancy, 
ID is associated with multiple adverse outcomes for both mother and child, including increased risk of bleeding, 
sepsis, maternal mortality, perinatal mortality and low birth weight5. In addition to these adverse effects, previous 
animal6–8 and human studies9,10 have suggested that ID may impair thyroid hormone metabolism. However, the 
majority of evidence available concerning the association between ID and thyroid dysfunction remains limited 
to children and adolescents11–13 or pregnant women14–17 whereas replication in wide samples of the general adult 
population has not been carried out. Accordingly, we aimed to test the hypothesis of an association between ID 
and Hypothyroxinemia and Hypotriiodothyroninemia in a wide population sample, representative of the general 
adult non-pregnant population of Spain (di@bet.es study).
Results
Characteristics of the study sample. Table 1 shows the clinical characteristics of the study sample. A total 
of 3846 individuals were included in the analysis. This sample was composed of 1793 men (45.9%), 1081 pre-meno-
pausal women (28.1%) and 998 post-menopausal women (25.9%). Mean age of the population was 50.0 ± 17.1 years 
(range 18–93 years). According to the ferritin concentrations, 13.6% of the population had ferritin levels <15 µg/L, 
14.4% had ferritin levels between 15–29 µg/L, 38.3% had ferritin levels between 30–99 µg/L, and 33.7% had ferritin 
levels ≥100 µg/L, so that 28.0% of the study sample had ID according to the proposed definition (ferritin <30 µg/L). 
Mean and medium urinary iodine (UI) concentrations were 133.8 ± 80.6 and 116.1 μg/g respectively. Mean and 
median concentrations of thyroid stimulating hormone (TSH), free thyroxine (FT4) and free triiodothyronine (FT3) 
were within the expected range, taking into consideration the exclusion criteria for this analysis.
Prevalence of ID. Figure 1 shows the proportion of the population with ID according to gender and age 
groups. As can be seen, ID was especially prevalent in pre-menopausal women, reaching prevalences of >50% in 
females in the 18 to 50 year old groups, with a drop in the prevalence in the 50–60 years decade and then a mild 
increase. Men also showed a slight increase in the prevalence with age. However women had consistently higher 
prevalence of ID than men in all the age groups.
Relation between Ferritin levels and thyroid hormones (linear model). Table 2 shows the mean concen-
trations of thyroid hormones in the study population according to ferritin levels, in a general linear model adjusted for 
age, sex, UI, BMI and smoking status. As ferritin levels decreased (>100, 30–100, 15–30, <15 µg/L), the adjusted mean 
concentrations of FT4 and FT3 descended (p for difference and p for trend for both comparisons <0.001). However, 
TSH adjusted mean concentrations remained unchanged (p for difference = 0.565, p for trend = 0.451).
Relation between Ferritin levels and thyroid hormones (logistic regression model). In multivar-
iate logistic regression models (also adjusted for age, sex, UI, BMI and smoking status), individuals with ferritin 
levels <30 μg/l were more likely to present hypothyroxinemia, and hypotriiodothyroninemia than the reference 
category with ferritin levels ≥30 µg/L. This association remained significant, considering a definition for these 
abnormalities as levels of FT4 and FT3 below p5 of the study population: OR 1.5 [IC95% 1.1–2.2] p = 0.024, and 
1.8 [IC95% 1.3–2.6] p = 0.001 respectively, and also considering a more stringent criteria (FT4 and FT3 < p2.5): 
OR 1.7 [IC95% 1.0–2.7] p = 0.044 and 2.0 [IC95% 1.2–3.3] p = 0.007 respectively. However, as in the linear model, 
no association was found between ID and higher TSH, neither ≥p95: 0.8 [IC95% 0.6–1.2] p = 0.348 nor ≥97.5 
(≥5.8 µUI/mL) OR 0.9 [IC95% 0.5–1.5] p = 0.676 (Table 3).
Subgroup analyses (logistic regression model). Figure 2 shows the results of the logistic regression anal-
yses in different population subgroups. As can be seen, although there were some small differences between groups, 
all the ORs tended toward the same direction, and no significant heterogeneity was seen in the results between men, 
pre-menopausal and post-menopausal women or according to the iodine nutrition status (iodine deficient vs. iodine 
replete). Subgroup analyses by using the more stringent criteria to define thyroid function abnormalities (low FT4 and 
FT3 < p2.5, and high TSH ≥ 97.5) were not performed due to the low number of subjects available for the analysis.
Discussion
Our results confirm an association between ID and hypothyroxinemia and hypotriiodothyroninemia in a large 
sample of thyroid disease free subjects representative of the Spanish general adult population, in models con-
trolled for possible confounding variables such as age, sex, BMI, smoking habit and UI.
These findings are in line with previous studies suggesting that ID may impair thyroid hormone production: 
ID has been shown to lower FT4 as well as FT3 in rats6–8, and small samples of humans with ID, with or without 
anemia, have been reported to have lower FT4 and FT3 levels than controls without ID9,10. Other previous studies 
have associated ID with the presence of goiter18, and iron supplementation in children with goiter and ID anemia 
has been shown to improve the efficacy of iodized oil administration, causing a reduction in glandular size19,20. ID 
has also been associated with changes in thyroid function in children and adolescents11,13, which improves after 
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its correction12. More recently, ID has been identified as an independent risk factor for the development of hypo-
thyroxinemia and thyroid dysfunction in pregnant women14–17. To our knowledge, this is the first epidemiological 
study reporting this association in a wide sample of the adult non-pregnant population, including adult men, as 
well as pre-menopausal and post-menopausal women.
Interestingly, the association between ID and the decreased levels of FT4 and FT3 found in our study is already 
significant for serum ferritin levels below 30 μg/l, which is in line with the level suggested by Mast et al.21. This 
threshold possibly corresponds to the so called “iron depletion state” defined by the WHO22 in which no hema-
tological, cerebral or muscular alterations are observed, however an objective low iron storage is present in the 
organism. In fact, according to our results, lower ID thresholds (e.g. <15 μg/L) could understate the hypothyrox-
inemia and hypotriiodothyroninemia associated with ID.
Figure 1. Proportion of the study population with ferritin levels <30 µg/L according to age and gender.
Ferritin (µg/L)
P for difference P for trend<15 15–30 30–100 >100
TSH (µUI/mL) 1.98 ± 0.07 2.07 ± 0.06 2.02 ± 0.04 2.05 ± 0.04 0.565 0.451
FT4 (pmol/L) 14.83 ± 0.10 15.06 ± 0.09 15.09 ± 0.06 15.33 ± 0.07 <0.001 <0.001
FT3 (pmol/L) 4.91 ± 0.03 4.91 ± 0.03 5.01 ± 0.02 5.11 ± 0.02 <0.001 <0.001
Table 2. Estimated mean concentrations of TSH, FT4, and FT3 in the study individuals divided according to 
their Ferritin levels. Data are estimated marginal means ± standard errors calculated in a general linear model, 
adjusted to age, sex, UI, BMI and smoking status.
Number (%) Mean ± SD Median Range
Age (years) 50.0 ± 17.1 18–93
Men 1767 (45.9)
Premenopausal women 1081 (28.1)
Postmenopausal women 998 (25.9)
Currently smoking 1023 (26.6)
BMI (kg/m2) 28.0 ± 5.1 12.2–61.3
Ferritin (µg/L)
 <15 523 (13.6)
 15–30 554 (14.4)
 30–100 1473 (38.3)
 ≥100 1296 (33.7)
UI (μg/g) 133.8 ± 80.6 116.1 20.0–632.5
TSH (µUI/mL) 2.33 ± 1.36 2.06 0.11–18.50
FT4 (pmol/L) 15.13 ± 2.04 15.05 8.21–26.24
FT3 (pmol/L) 5.01 ± 0.72 4.95 2.59–11.95
Table 1. Clinical characteristics of the study sample (3846 individuals free of thyroid disease). BMI: Body mass 
index. UI: Urinary iodine.
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ID may alter the synthesis of thyroid hormones by multiple mechanisms: ID induces ineffective erythropoie-
sis, thus reducing the transport of oxygen to the different tissues required for multiple enzymatic reactions23. ID 
has also been shown to increase in-vitro hepatic reverse triiodothyronine deiodination, suggesting that under 
conditions of ID, thyroid hormones tend to be metabolized by an inactivating route24. Also, ID may lower thy-
roperoxidase activity and therefore interfere with the synthesis of thyroid hormones25. Although these mecha-
nisms described could be explanatory, our results suggest the implication of additional hypothalamic-pituitary 
mechanisms, given the lack of TSH response to the decrease in the levels of peripheral hormones. Accordingly, 
Figure 2. Adjusted Odd Ratios (ORs) for presenting high TSH (≥p95) (A), low FT4 (p < 5) (B), and low FT3 
(<p5) (C), according to Ferritin levels in different population subgroups. Foot: Adjusted ORs were calculated 
by logistic regression adjusted to age, sex, UI, BMI and smoking status. Homogeneity of the ORs was tested with 
the Breslow-Day test.
Total number Number (%) Adjusted OR 95% CI p Number (%) Adjusted OR 95% CI p
TSH ≥ 4.7 µUI/mL (p95) TSH ≥ 5.8 µUI/mL (p97.5)
Ferritin (µg/L)
≥30 2769 135 (4.9) 1 68 (2.5) 1
<30 1077 57 (5.3) 0.8 (0.6–1.2) 0.348 28 (2.6) 0.9 (0.5–1.5) 0.676
FT4 < 12.0 pmol/L (p5) FT4 < 11.5 pmol/L (p2.5)
Ferritin (µg/L)
≥30 2769 117 (4.2) 1 52 (1.9) 1
<30 1075 73 (6.8) 1.5 (1.1–2.2) 0.024 41 (3.8) 1.7 (1.0–2.7) 0.044
FT3 < 3.9 pmol/L (p5) FT3 < 3.8 pmol/L (p2.5)
Ferritin (µg/L)
≥30 2768 111 (4.0) 1 52 (1.9) 1
<30 1074 76 (7.1) 1.8 (1.3–2.6) 0.001 41 (3.8) 2.0 (1.2–3.3) 0.007
Table 3. Prevalence (%) and adjusted Odd Ratios (OR) for presenting high TSH, low FT4 and low FT3 in the 
study. Individuals according to their Ferritin levels (<30 vs ≥30 µg/L). Adjusted ORs were calculated by logistic 
regression adjusted to age, sex, UI, BMI and smoking status.
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the experiments carried out by Tang et al. in iron deficient rats subjected to low temperatures, showed decreased 
levels of TSH, FT4 and FT3, which reverted to normal if stimulated with synthetic thyrotropin releasing hormone 
(THR), suggesting that ID may impair the hypothalamic secretion of THR26. In line with this observation, the 
study from Eftekhari in Iranian adolescents with ID, showed that despite increases in FT3 and FT4 concentra-
tions, the TSH concentration was unaffected by iron supplementation12. Since no separate mechanism on its own 
fully explains the results found in our study, it is likely that a combination of mechanisms may be involved.
Our results are limited due to the cross sectional nature of the analyses, so we cannot infer causal mechanisms, 
however, the results may have clinical implications, especially in pre-menopausal women, where ID is more prev-
alent. In fact hypothyroxinemia is associated with numerous factors that complicate gestation, such as increased 
preterm birth or the development of gestational diabetes27 and the development of newborns such as language 
delay28 or lower intellectual coefficient29. Recently, the persistence of low T4 levels in children born to mothers 
with hypothyroxinemia and ID until the tenth postnatal day has also been demonstrated30. Thus, the implication 
of ID in the pathogenesis of these thyroid disorders in pregnancy could open a new perspective for its prevention 
and early intervention and requires further research. On the other hand, hypothyroxinemia and hypotriiodothy-
roninemia have not been sufficiently studied in other population groups, so that the existence of some harmful 
effects in the non-pregnant population cannot be discarded.
In conclusion, we report an association between ID and hypothyroxinemia and hypotriiodothyroninemia 
in the Spanish general adult population. Several hypothalamic-pituitary and peripheral mechanisms may be 
involved. Further prospective and experimental studies are needed to establish causal mechanisms and to expand 
knowledge in this field.
Methods
The Di@bet.es Study is a national, cross sectional, population based survey that was conducted in 2009–10. A 
cluster sampling design was used to select participants to form a representative random sample of the Spanish 
population. In the first stage, 100 health centers or their equivalent were selected from all around the country, 
with a probability proportional to their population size, after which 100 individuals aged ≥18 years were ran-
domly selected from each health center. Of the eligible adults, 55.8% attended for examination, of whom 9.9% 
were excluded (institutionalized, severe disease, pregnancy or recent delivery), giving a final sample of 5061 indi-
viduals. In 90% of this sample, thyroid function studies were performed31.
For the present analysis, we excluded all the subjects with a previous thyroid disease diagnosis, and/or tak-
ing interfering medications (levothyroxine, thionamides, amiodarone or lithium). Individuals with a positive 
TPOAbs test (≥50 IU/ml), or with very high (>20 mIU/L) or suppressed (<0.1 mIU/L) TSH levels, and/or with 
severe iodine deficiency (UI < 20 μg/g) were also excluded.
The research was carried out in accordance with the Declaration of Helsinki (2008) of the Word Medical 
Association. Written informed consent was obtained from all the participants. The study was approved by the 
Ethics and Clinical Investigation Committee of the Hospital Regional Universitario de Málaga (Malaga, Spain) in 
addition to other regional ethics and clinical investigation committees all over Spain.
Variables and procedures. The participants were invited to attend a single examination visit at their health 
center. Information was collected using an interviewer administered structured questionnaire, followed by a 
physical examination and blood sampling.
Information on demographic characteristics and smoking status was obtained by questionnaire. Medical his-
tory and medications were also recorded. Menopause was considered in women who reported more than 12 
months of amenorrhea without any other obvious pathological or physiological cause. Weight and height were 
measured and the body mass index was calculated by standardized methods. Blood samples were obtained in 
fasting conditions, were immediately centrifuged and the serum was frozen until analysis. A casual urinary sam-
ple (in the morning and in fasting state) was also collected and samples were frozen until analysis. Samples were 
managed and provided by the Hospital Regional Universitario de Málaga-IBIMA Biobank that also belongs to 
the Andalusian Public Health System Biobank, and the biorepository CIBERDEM (Instituto de Salud Carlos III) 
managed by IDIBAPS Biobank.
TSH, FT4, FT3 and TPOAb concentrations were analyzed using an electrochemiluminescence immunoassay 
(Modular Analytics E170, cobas e 602, Roche Diagnostics, Basel, Switzerland). The functional sensitivity of the 
TSH assay was 0.014 mIU/L. The intra-assay coefficients of variation were: TSH, 1.5–1.2%; FT4 1.8–1.6%; FT3 
1.3–2.0% and TPOAb 4.8–2.8%. The inter-assay coefficients of variation for the low and high levels of serum 
TSH, FT4, FT3 and TPOAb quality control materials were 3.5 and 2.7%, 4.17 and 2.64%, 3.78 and 2.21%, and 
8.5 and 5.2%, respectively. All samples were analyzed at the laboratory of Biochemistry of the Hospital Regional 
Universitario de Malaga, which attends a population of 487,857 people from the city of Malaga.
UI was analyzed using the modified method of Benotti and Benotti32. The intra- and inter-assay coefficients of 
variation of UI assay were 2.01% and 4.53%, respectively.
Ferritin levels were analysed by immunochemiluminescence in the Architect I2000 analyzer (Abbott 
Laboratories SA, Madrid, Spain). The intra- coefficients of variation of the assay was 5.6% and the functional 
sensitivity 0.1055 ng/mL. ID was defined as ferritin levels <30 µg/L as proposed by Mast et al.21.
Statistical analysis. To test the association between ferritin and thyroid hormones, we calculated the esti-
mated mean levels of TSH, FT4 and FT3 in different ferritin categories in general linear models adjusted for 
possible confounders such us age, sex, UI, BMI and smoking status. Because they were nonnormally distributed, 
serum TSH values were log-transformed.
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We also constructed logistic regression models to calculate the odds ratios for having low FT4 levels (<p5 
and <p2.5) low FT3 levels (<p5 and <p2.5) and high TSH (>p95 and >p97.5), according to the ferritin levels 
(dichotomized as <30 vs ≥30 µg/L) adjusted for these same variables (age, sex, UI, BMI and smoking status). We 
used the Breslow-Day test to test for homogeneity of the odds ratios according to various clinical categories (men 
vs. pre-menopausal vs. post-menopausal women, iodine deficient vs. iodine replete).
Reported p values were based on two-sided tests with statistical significance set at 0.05.
Data availability. The datasets generated during and/or analyzed during the current study are available from 
the corresponding author on reasonable request.
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